Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Executive Summary
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.
You may also be interested in...
Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar
Mylan has struck a deal to commercialize Lupin's biosimilar Enbrel (etanercept), continuing to seize opportunities beyond existing alliances to ensure an early play in certain key markets. Longstanding Mylan partner Biocon maintains that it won't lose out either, though the outlook for their partnered etanercept is unclear, at least for now.
Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar
Mylan has struck a deal to commercialize Lupin's biosimilar Enbrel (etanercept), continuing to seize opportunities beyond existing alliances to ensure an early play in certain key markets. Longstanding Mylan partner Biocon maintains that it won't lose out either, though the outlook for their partnered etanercept is unclear, at least for now.
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.